The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the evolving strategies to improve the efficacy of CAR T-cell therapy in multiple myeloma. He highlights the potential benefits of dual-targeting approaches, combining with other agents, and strategies to enhance resistance to T-cell exhaustion. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know that not all the patients that are treated are actually remaining in remission. There are kinds of relapses and these relapses are due to often a loss of the antigen that is targeted by the CAR T-cells. So probably by increasing the targets like coming from a monotherapy to a dual-targeting CAR T-cell therapy will increase the efficacy and probably also the likelihood of responses. Also, the combination of bispecific antibodies and CAR T-cells is obviously increasing the efficacy of CAR T-cell therapy...
We know that not all the patients that are treated are actually remaining in remission. There are kinds of relapses and these relapses are due to often a loss of the antigen that is targeted by the CAR T-cells. So probably by increasing the targets like coming from a monotherapy to a dual-targeting CAR T-cell therapy will increase the efficacy and probably also the likelihood of responses. Also, the combination of bispecific antibodies and CAR T-cells is obviously increasing the efficacy of CAR T-cell therapy. In addition, we know that the CAR T-cells are not persisting forever. So strategies are increasingly used to improve persistence like adding, for example, IMiDs or CELMoDs to improve persistence or some other strategies are to actually modify the CAR T-cells by taking or deleting inhibitory receptors from the T-cells to make the CAR T-cells resist T-cell exhaustion. So there are quite a lot of strategies now available and I think they will all help to improve the efficacy of CAR T-cell therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
